期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

重组人可溶性补体受体1型SCR15-18片段表达纯化及生物活性鉴定 被引量：6

Expression,purification and bioactivity identification of recombinant SCR15-18 domain of human soluble complement receptor type 1
下载PDF
导出
摘要 目的获得高表达、高纯度和高活性的可溶性补体受体1型SCR15-18(sCR1-SCR15-18)蛋白。方法重组原核表达载体pET32a-sCR1-SCR15-18在大肠杆菌BL21中经不同IPTG浓度、诱导时间和温度诱导表达,超声破菌,提取包含体,经Ni2+-NTA亲和层析后,选择不同氧化还原条件进行复性,进而检测其生物学活性。结果得到了有较高表达量、较高纯度和较好生物学活性的sCR1-SCR-15-18蛋白。结论优化了sCR1-SCR15-18蛋白的表达、纯化和复性的参数,所获结果为进一步动物体内保护实验研究奠定了基础。 Objective To prepare highly expressed, purified and refolded SCR15-18 of human soluble complement receptor type 1 （ sCR1-SCR15-18 ） protein. Methods The expression of recombinant pET32- sCR1-SCR15-18 in E. coli.. BL21 was induced by IPTG of different concentrations for different time period under different temperatures and the bacteria were split by sonication. The sCR1-SCR15-18 protein was purified by Ni^2＋ -NTA resin affinity chromatography. The purified protein was refolded under different conditions. Then the bioactivity of the protein was analyzed. Results The sCR1-SCR15-18 protein of high expression, purity and bioactivity was attained. Conclusion The parameters of expression, purification and refolding of sCR1- SCR15-18 protein were optimized, which may pave a way for further studies.
作者 谭兵 张德纯 汪正清
机构地区 第三军医大学基础医学部微生物学教研室 重庆医科大学基础医学院病原生物学教研室
出处 《第三军医大学学报》 CAS CSCD 北大核心 2007年第10期892-895,共4页 Journal of Third Military Medical University
基金 国家自然科学基金(30471723)~~
关键词 可溶性补体1型受体 表达 包含体 纯化 复性 soluble complement receptor type 1 expression inclusion body purification refolding
分类号 R392.33 [医药卫生—免疫学] R392.11 [医药卫生—免疫学]
  • 相关文献

参考文献9

  • 1Weisman H F,Bartow T,Leppo M K,et al.Soluble human complement receptor type 1:in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis[J].Science,1990,249(4965):146-151.
  • 2罗雪,汪正清.补体受体1型的结构功能及sCR1基因克隆表达的策略[J].创伤外科杂志,2005,7(6):475-477. 被引量：1
  • 3Quigg R J.Use of complement inhibitors in tissue injury[J].Trends Mol Med,2002,8(9):430-436.
  • 4Lazar H L,Bokesch P M,Van-Lenta F,et al.Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass[J].Circulation,2004,110(11 Suppl 1):Ⅱ274-Ⅱ279.
  • 5罗雪,汪正清.人sCR1结合C3b结构域基因的克隆及在大肠杆菌中高效表达[J].第三军医大学学报,2005,27(15):1551-1554. 被引量：7
  • 6Ishii N,Kato H,Wang P H.Observation by electron microscopy on recombinant soluble human complement receptor type 1 (sCR1) and its derivative,aglyco-sCR1,from CHO cells[J].Enzyme Microb Technol,2003,33(4):482-487.
  • 7Morgan B P,Rushmere N K,Harris C L.Therapeutic uses of recombinant complement receptors[J].Biochem Soc Trans,1998,26(1):49-54.
  • 8Hart M L,Walsh M C,Stahl G L.Initiation of complement activation following oxidative stress.In vitro and in vivo observations[J].Mol Immunol,2004,41(2-3):165-171.
  • 9萨姆布鲁克J 拉塞尔DW 黄培堂 译.分子克隆实验指南[M](第3版)[M].北京:科学出版社,2002.463-465.

二级参考文献26

  • 1Stahl G L, Xu X, Hao L, et al. Role for the alternative complement pathway in ischemia/reperfusion injury [J]. Am J Pathol, 2003, 162 (2): 449 -455.
  • 2Noriyuki I, Hisamune K, Wang P C. Observation by electron microscopy on recombinant soluble human complement receptor type 1 ( sCR1 ) and its derivative, aglyco-sCR1, from CHO cells [ J ]. Enzyme and Microbial Technology, 2003, 33 (4): 482 -487
  • 3Mizuno M, Nishikawa K, Okada N, et al. Soluble complement receptor type 1 protects rats from lethal shock induced by anti-Crry antibody following Lipopolysaccharide priming [ J ]. Int Arch Allergy Immunol,2002, 127 (1): 55-62.
  • 4Azimzadeh A, Zorn G L3rd, Blair K S, et al. Hyperacute lung rejection in the pig-to-human model. 2. Synergy between soluble and membrane complement inhibition [ J ]. Xenotransplantation, 2003, 10 (2): 120 - 131.
  • 5Dodd I, Mossakowska D E, Camilleri P, et al. Overexpression in Escherichia coli, folding, purification, and characterization of the first three short consensus repeat modules of human complement receptor type 1 [J]. Protein Expr Purif, 1995, 6 (6): 727 -736.
  • 6Mossakowska D, Dodd I, Pindar W, et al. Structure-activity relationships within the N-terminal short consensus repeats (SCR) of human CR1 (C3b/C4b receptor, CD35): SCR 3 plays a critical role in inhibition of the classical and alternative pathways of complement activation[J]. Eur J Immunol, 1999, 29 (6): 1955-1965.
  • 7Klickstein LB,Bartow TJ,Miletic V,et al.Identification of distinct C3b and 4Cb recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis [J].Exp Med,1988,168(5):1699-1717.
  • 8Makrides SC,Nygren PA,Andrews B,et al.Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor[J].Pharmacol Exp Ther,1996,277:534-542.
  • 9Paul BM,Claire LH.Complement therapeutics:history and current progress[J].Mol Immunol,2003,40(2-4):159-170.
  • 10Fiane AE,Compstatin A.Peptide inhibitor of C3,prolongs survival of ex vivo perfused pig xenografts[J].Xenotransplantation,1999,6:52-65.

共引文献60

同被引文献87

引证文献6

二级引证文献19

第三军医大学学报
2007年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部